Merck & Co faces Fosamax test case on jaw osteonecrosis claims
This article was originally published in Scrip
Executive Summary
Merck & Co is facing about 900 product liability suits alleging that osteonecrosis of the jaw (ONJ) is associated with its oral bisphosphonate, Fosamax (alendronate), the company said in an August 3rd regulatory filing with the US Securities and Exchange Commission.